Latest Breaking News On - Advanced breast - Page 1 : comparemela.com

Novartis : Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high risk node negative disease

Novartis : Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high risk node negative disease
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaFrance generalUnited statesSan antonioSloan simpsonIsabella zinckSatoshi sugimotoParag mahantiNicole zinsli sommMarlena abdinoorJeff legosJonathan grahamMichael meoImke kappesDenisea yardleyEuropean society of medical oncology congress

US Preventive Services Task Force Recommends Breast Cancer Screenings Begin at Age 40

The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.

Wanda nicholsonJohn wongUniversity of ottawaUs preventive services taskUs preventive services task forceUs preventive services taskServices task forceTask forceFinal recommendation statement breast cancerForce issues final recommendation statementAdvanced breast

PADA-1 Trial: ctDNA Monitoring for Acquired ESR1 Mutations in Advanced Breast Cancer

Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).

Breast cancerAdvanced breastHr breast cancerHr positive breast cancerBreast cancer treatmentEsr1 mutationsBiomarker testingEsr1 testingPada 1Circulating tumor dnaAromatase inhibitorPatient monitoring

Endocrine Therapy Effective Subsequent Advanced Breast Cancer Treatment

Endocrine therapy, particularly when administered in combination with Verzenio (abemaciclib), is effective when compared with chemotherapy among patients with metastatic breast cancer who experienced disease progression on Ibrance (palbociclib), according to recently published research.

San antonioUnited statesCdki verzenioDrug administrationUniversity cancer hospitalKey laboratory of carcinogenesisTranslational research ministry of educationKey laboratoryTranslational researchPeking university cancer hospitalLower cost improve adherenceZanidatamab plus ibranceFaslodex show promiseAdvanced breastClinical implicationsMetastatic breast

AURKA Pathway Gains Ground as Targetable Option in Metastatic Breast Cancer

The AURKA inhibitor alisertib has emerged as an agent of particular note, demonstrating early signals of efficacy with a manageable safety profile for the treatment of patients with locally advanced or metastatic breast cancer whose disease is resistant to endocrine therapies.

Mayo clinic in rochesterUnited statesKarthikv giridharTufiac haddadAntonio dassoroHouj auroraDigital healthMayo clinic comprehensive cancer centerMayo clinic college of medicineAmerican society of clinical oncology annual meetingMayo clinicMayo clinic collegeAntoniod assoroDemonstrates efficacyAdvanced breastSeveral tumor